Evidence map›Paper›PMID 38331394›Full record

ArticleJournal of the National Cancer Institute2024

Association of differential censoring with survival and suboptimal control arms among oncology clinical trials.

Eric J Hsu, Timothy A Lin, Dor R Dabush, Zachary McCaw, Alex Koong, Christine Lin, Joseph Abi Jaoude, Roshal Patel, Ramez Kouzy, Molly B El Alam and 14 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 9 institutions in 2 countries.

Eric J HsuDepartment of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-6743-2399
Timothy A LinDivision of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dor R DabushDavidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel.
Zachary McCawDepartment of Biostatistics, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Alex KoongDivision of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christine LinDivision of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Joseph Abi JaoudeDivision of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Roshal PatelDivision of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ramez KouzyDivision of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Molly B El AlamDivision of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sonal NoticewalaDivision of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yumeng YangSchool of Bioinformatics, University of Texas Health Science Center at Houston, Houston, TX, USA.
Alexander D SherryDivision of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Clifton D FullerDivision of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Charles R ThomasRadiation Oncology, Dartmouth Cancer Center, Geisel School of Medicine, Lebanon, NH, USA.
Chad TangDivision of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Pavlos MsaouelDepartment of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-6505-8308
Prajnan DasDivision of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bo HuangPfizer Inc, Groton, CT, USA.
Lu TianDepartment of Health Research and Policy, Stanford University, Stanford, CA, USA.ORCID 0000-0002-5893-0169
Ryan SunDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0003-1176-1561
J Jack LeeDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Tomer MeirsonDavidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel.ORCID 0000-0002-5011-5477
Ethan B LudmirDivision of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-5472-5344
The University of Texas MD Anderson Cancer Center · USDartmouth College · USPfizer (United States) · USRabin Medical Center · ILStanford Health Care · USTel Aviv University · ILThe University of Texas Health Science Center at Houston · USThe University of Texas Southwestern Medical Center · USUniversity of North Carolina at Chapel Hill · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA023108
6 · The paper itself

Abstract

Differential censoring, which refers to censoring imbalance between treatment arms, may bias the interpretation of survival outcomes in clinical trials. In 146 phase III oncology trials with statistically significant time-to-event surrogate primary endpoints, we evaluated the association between differential censoring in the surrogate primary endpoints, control arm adequacy, and the subsequent statistical significance of overall survival results. Twenty-four (16%) trials exhibited differential censoring that favored the control arm, whereas 15 (10%) exhibited differential censoring that favored the experimental arm. Positive overall survival was more common in control arm differential censoring trials (63%) than in trials without differential censoring (37%) or with experimental arm differential censoring (47%; odds ratio = 2.64, 95% confidence interval = 1.10 to 7.20; P = .04). Control arm differential censoring trials more frequently used suboptimal control arms at 46% compared with 20% without differential censoring and 13% with experimental arm differential censoring (odds ratio = 3.60, 95% confidence interval = 1.29 to 10.0; P = .007). The presence of control arm differential censoring in trials with surrogate primary endpoints, especially in those with overall survival conversion, may indicate an inadequate control arm and should be examined and explained.

Indexed as

NeoplasmsClinical Trials, Phase III as TopicHumansMedical OncologyResearch Design

Identifiers

PMID38331394
PMCPMC12187001
OpenAlexW4392316504

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.